Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,665 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type I Diabetes Clear all
Completed Phase 1 Interventional

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

NCT05184868
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
AT247, NovoLog, Fiasp
Drug
Lead sponsor
Arecor Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Telehealth Intervention for Youth With T1DM

NCT01782547
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Telehealth Intervention, Usual Care
Behavioral · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 21, 2026, 9:42 AM EDT
Completed No phase listed Observational

The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus

NCT05908448
View directory record Official record
Conditions
T1DM - Type 1 Diabetes Mellitus
Interventions
13 CGM (continuous glucose monitor)
Device
Lead sponsor
Sinocare
Industry
Eligibility
2 Years to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Metabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes

NCT04955691
View directory record Official record
Conditions
Type1diabetes, Low Carbohydrate Diet
Interventions
low carbohydrate diet, standard carbohydrate diet
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes

NCT02544321
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bromocriptine, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

NCT01293461
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Peripheral Diabetic Neuropathy
Interventions
CBX129801, Placebo
Drug
Lead sponsor
Cebix Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Escondido, California • Tustin, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Overnight Closed Loop Study in U.S.

NCT01857973
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Hybrid Closed Loop
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Escondido, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 21, 2026, 9:42 AM EDT
Recruiting Not applicable Interventional

Health Behavior Intervention for Adults With Type 1 Diabetes

NCT05823142
View directory record Official record
Conditions
Type1diabetes
Interventions
CB Sleep
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 40 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 21, 2026, 9:42 AM EDT
Recruiting Not applicable Interventional

Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM

NCT07296276
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CareSens Air 3 primary insertion, CareSens Air 3 secondary insertion
Device
Lead sponsor
i-SENS, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Adjunctive Metformin Therapy in Double Diabetes

NCT01334125
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional

A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management

NCT01829555
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
contingency management
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
15 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

NCT04585776
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
LY900014, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

NCT00612040
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

NCT02603510
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

NCT03751007
View directory record Official record
Conditions
Diabetes type1
Interventions
AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
Biological · Drug
Lead sponsor
Precigen Actobio T1D, LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 21, 2026, 9:42 AM EDT
Recruiting Not applicable Interventional

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus, Type I, Diabetes, Type II, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus Type II, Diabetes Type 2 on Insulin
Interventions
Bionic Pancreas, Routine Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 21, 2026, 9:42 AM EDT
Terminated Not applicable Interventional

Camp Based Multi-component Intervention for Families of Young Children With Type 1 Diabetes

NCT04279587
View directory record Official record
Conditions
Type1diabetes
Interventions
Residential camp
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 5 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 21, 2026, 9:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Type 1 Diabetes Mellitus and Increased Weight on Gut Microbiome and Urine Metabolome Profiles in Children

NCT02938806
View directory record Official record
Conditions
Obesity, Overweight, Type 1 Diabetes Mellitus
Interventions
No intervention
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes

NCT00592072
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Medium chain fatty acid (Octanoic and Decanoic acid), Splenda (Placebo Control)
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study

NCT01591681
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pump suspension
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
15 Years to 45 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Telemedicine for Reach, Education, Access, and Treatment for Diabetes Self-Management Education and Support

NCT06626347
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
TREAT-ED Virtual Group Diabetes Self-Management Education and Support
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 9:42 AM EDT
Terminated No phase listed Observational Results available

Novel mHealth Physical Activity Intervention for Youth With Type 1 Diabetes Mellitus

NCT06018844
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
NUDGE
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
13 Years to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Early Phase 1 Interventional

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, hyaluronidase, Lispro-PH20
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

NCT02715193
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Diabetes
Interventions
REMD-477, Placebo Comparator
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 21, 2026, 9:42 AM EDT